Microfluidics Market Size, Share & Trends Analysis growing at a CAGR of 11.99% from 2025 to 2030
The global microfluidics market size was estimated at USD 37.49 billion in 2024 and is anticipated to reach USD 73.85 billion by 2030, growing at a CAGR of 11.99% from 2025 to 2030. This growth is primarily driven by the increasing adoption of microfluidic devices across various fields of research and diagnostics.
Key Market Trends & Insights
- North America microfluidics market dominated the global market with a revenue share of 42.3% in 2024.
- Advanced healthcare infrastructure, robust research and development investments, and the presence of industry leaders drive the U.S. microfluidics market.
- By material, the polydimethylsiloxane (PDMS) segment held the highest revenue share of 36.60% in 2024.
- By technology, lab-on-a-chip segment held the highest market share of 37.49% in 2024
- By product, the microfluidic components segment held the largest revenue share in 2024 and is anticipated to grow at the fastest CAGR over the forecast period.
Market Size & Forecast
- 2024 Market Size: USD 37.49 Billion
- 2030 Projected Market Size: USD 73.85 Billion
- CAGR (2025-2030): 11.99%
- North America: Largest market in 2024
Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/microfluidics-market/request/rs1
For instance, in March 2025, a U.S.-based study introduced a microfluidics-based analytical technique, improving detection and accuracy. It promised to revolutionize chemical analysis, with applications in pharmaceuticals, environmental testing, and food safety. Microfluidic approaches have been effectively used to determine glucose levels, detect infection, diagnose dry eye disease, and assess vascular endothelial growth factor levels. Such applications are expected to positively affect market growth in the coming years.
Advancements and Adoption of Microfluidics in Diagnostic Healthcare
Rising hospital expenditures and frequent patient revisits drive the demand for efficient diagnostic devices. Prehospital diagnostic solutions, such as at-home blood glucose monitoring, are helping reduce hospital visits and inpatient stays. Key industry players’ launch of Point-of-Care (POC) products has enabled earlier disease detection and improved patient outcomes. With ongoing technological advancements, companies are differentiating their offerings through features like minimally invasive sampling, enhanced accuracy, and rapid turnaround times, significantly contributing to the growth of the in vitro diagnostics (IVD) market.
Leading companies such as Abbott, Roche, and Danaher actively integrate microfluidics into their diagnostic platforms to enhance performance and usability. Digital microfluidics is also emerging as a promising area, with several players investing in its development. For example, in August 2022, HORIBA partnered with SigTuple to accelerate the rollout of AI100, an AI-driven digital pathology solution in the Indian subcontinent. The platform integrates robotics, artificial intelligence, cloud computing, and microfluidics to deliver affordable, high-quality diagnostic solutions.
